Venture capital funds found 612 companies in which to invest $3.67 billion in Q2. Of this, $1.5 billion (41%) was first-time financing, according to a report by PricewaterhouseCoopers and the National Venture Capital Association. This is only slightly ahead of the action in Q1, in which 141 transactions were first-time, and far behind the pace we enjoyed earlier this decade.

The biotech sector was the big winner in a shrinking market, with funding up 54% to $888 million over 85 deals. The software business was flat quarter-over-quarter at 4644 million over 135 transactions. Investments in internet companies fell 15% to $524 million via 124 deals. Clean technology showed considerable growth, up 15% to $274 million, with 42 transactions closed.

Wall Street's equity market offers full slate this week - with 5 IPOs and 6 Secondaries on the docket.

Those deals tentatively scheduled to price include:

IPOs:

Tuesday

Venture Financial Group (VNBK), a 1.8M-share IPO for this bank holding company. Keefe, Bruyette & Woods and D.A. Davidson are the lead managers. Filing range: $21.00-$23.00

Zars Pharma (ZARS), a 5.75M-share IPO for this pharmaceuticals company. Cowen and Co. and CIBC are the lead managers. Filing range: $14.00-$16.00.